---

---

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C.  20549

 

______________________

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16 of the

 

Securities Exchange Act of 1934

 

For the month of September 2015

 

Commission File Number: 001-35464

 

ReWalk Robotics Ltd.

 

(Translation of registrant’s name into English)

 

Kochav Yokneam Building, Floor 6

P.O. Box 161

Yokneam Ilit, Israel

 (Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ¨ No x

 

 If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  82-________

 

 

EXPLANATORY NOTE

 

On September 16, 2015, ReWalk Robotics Ltd. (the “Company”) issued a press release announcing the appointment of Deborah DiSanzo to the Company’s Board of Directors. A copy of the press release is attached to this Form 6-K as Exhibit 99.1. 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  

 

	ReWalk Robotics Ltd.
Date: September 16, 2015	By:	/s/ Larry Jasinski
		Name: Larry Jasinski Title:   Chief Executive Officer

 

 

 

 

EXHIBIT INDEX

 

The following exhibit is filed as part of this Form 6-K:

 

Exhibit

Description

 

99.1

Press release titled “ReWalk Robotics Appoints Deborah DiSanzo to its Board of Directors,” dated September 16, 2015.

 

 

 

 

 

 

 

Exhibit 99.1

 

 

For Immediate Release

 

ReWalk Robotics Appoints Deborah DiSanzo to its Board of Directors

 

-Distinguished Career in Medical Device Industry; Former CEO of Philips Healthcare-

 

 

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, September 16, 2015 – ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk”), the leading global exoskeleton developer and manufacturer, today announced that Deborah DiSanzo has been appointed to its Board of Directors, effective immediately.

 

“We are very pleased to welcome Deborah DiSanzo to our board and draw upon her expertise as a seasoned medical device executive and leader in our industry as we work to expand our commercialization efforts for the ReWalk exoskeleton and build shareholder value,” said Larry Jasinski, Chief Executive Officer.

 

“Deborah is a respected industry leader whose depth of global operational expertise will bring valuable insights as we look to expand our global footprint and bring the hope of walking again within reach of more individuals around the world. Deborah’s wealth of experience will add an important perspective to our board as ReWalk Robotics continues to be positioned for global commercial success. I am confident Deborah will make a meaningful and immediate contribution to our distinguished board of directors,” added Jeff Dykan, Chairman of the Board of Directors of ReWalk.

 

Deborah DiSanzo commented, “I am proud to join ReWalk at this point in its journey, as the company advances its commercialization efforts to transform the lives of many more individuals with lower limb disabilities. I look forward to working with ReWalk management and my accomplished colleagues on the Board of Directors to expand the reach of ReWalk exoskeletons around the world.”

 

Deborah DiSanzo has had a distinguished career in the medical device industry. From 2012 to 2014, Deborah was Chief Executive Officer of Philips Healthcare. Previously at Philips Healthcare, she was CEO of Patient Care and Clinical Informatics (PCCI), CEO of Healthcare Informatics and Patient Monitoring and General Manager of Patient Monitoring. Deborah joined Philips in 2001 when Philips acquired Agilent’s Healthcare Solutions Group. She received her B.S. from Merrimack College and M.B.A. from Babson College.

 

Forward Looking Statements

In addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk’s future performance and, in some cases, may be identified by words like “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek” and similar terms or phrases. The forward-looking statements contained in this press release are based on management’s current expectations, which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of ReWalk’s control. Important factors that could cause ReWalk’s actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk’s expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand to new markets; ReWalk’s ability to maintain and grow its reputation and the market acceptance of our products; ReWalk’s ability to achieve reimbursement from third-party payors for our products; ReWalk’s expectations as to its clinical research program and clinical results; ReWalk’s ability to improve its products and develop new products;  ReWalk’s ability to maintain adequate protection of its intellectual property and to avoid violation of the intellectual property rights of others; ReWalk’s ability to gain and maintain regulatory approvals; ReWalk’s ability to maintain relationships with existing customers and develop relationships with new customers; and other factors discussed under the heading “Risk Factors” in the U.S. Annual Report on the Form 20-F for the year ended December 31, 2014  filed with the U.S. Securities and Exchange Commission on February 27, 2015 and other documents filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk’s actual results to differ from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

 

ReWalk Robotics Appoints Deborah DiSanzo to its Board of Directors

Page 2

 

 

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk’s mission is to fundamentally change the health and life experiences of individuals with lower limb disabilities. Founded in 2001, ReWalk has headquarters in the US, Israel and Germany. For more information on the ReWalk systems, please visit http://www.rewalk.com.

 

ReWalk® is a registered trademark of ReWalk Robotics Ltd. in Israel.

 

Contacts:

 

For Investors:

Lisa M. Wilson

President

In-Site Communications, Inc.

Investor Relations

Tel: (212) 452-2793

lwilson@insitecony.com

 

For Media:

Jennifer Wlach

Mercury LLC

Tel: (202) 551-1454

jwlach@mercuryllc.com